Received Mar 18, 2026
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| TYP | TYPHOID LIVE ORAL TY21A (VIVOTIF) | BERNA BIOTECH, LTD. | 2 | Unknown | PO / MO |
The patient missed the third dose of Vivotif; Case reference number US-BN-2025-001435 is a spontaneous case initially received from a consumer via Communications (reference number: USBAV25-2095) on 21-Aug-2025 and concerns a 24-year-old male patient. The patient's medical history and concomitant medication details were not provided. On 16-Aug-2025, the patient took the first dose of Vivotif (batch number: unknown) at an unknown dose, orally, for indication of typhoid immunization. On 18-Aug-2025, two days after the first dose, the patient took the second dose of Vivotif (batch number: unknown) at an unknown dose, orally. On 20-Aug-2025, the patient missed the third dose of Vivotif (explicitly coded as 'missed dose'). At the time of the initial report, it was unknown if the patient experienced any of adverse events due to Vivotif. No further information was provided.; Reporter's Comments: A 24-year-old male patient missed the third dose of Vivotif for indication of typhoid immunization, which is considered as missed dose. It was unknown if the patient experienced any of adverse events due to Vivotif. Product dose omission issue is considered as listed per company convention. The patient's medical history and concomitant medication details were not provided. Product dose omission issue is not related to the suspect vaccine, but to a human factor. This case is considered as non-serious.; Sender's Comments: A 24-year-old male patient missed the third dose of Vivotif for indication of typhoid immunization, which is considered as missed dose. It was unknown if the patient experienced any of adverse events due to Vivotif. Product dose omission issue is considered as listed per company convention. The patient's medical history and concomitant medication details were not provided. Product dose omission issue is not related to the suspect vaccine, but to a human factor. This case is considered as non-serious.
Comments: NONE